Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial
Company Responds to Rapidly Growing COVID-19 Cases by Increasing Mechanisms to Make Lung Healing Cells Available
“Based on my clinical experience with the JadiCells, their therapeutic effects are unparalleled in comparison to any other stem cell therapy,” said Dr.
Previously the Company has demonstrated superior activity of JadiCells to other stem cells, as well as identifying mechanisms of action2,3. The JadiCell is currently in Phase III for COVID-19 ARDS4, has been granted IND numbers for COPD5, and Chronic Traumatic Encephalopathy6, and is in late preclinical development for Idiopathic Pulmonary Fibrosis7.
“We are thankful for the brave doctors that approach us and work with us to provide accelerated access to potentially life-saving cell therapies such as JadiCells to their patients,” said
1 Therapeutic Solutions International Successfully Treats "No Option" Patients with its JadiCell™ Stem Cell Therapy While Advancing Preparations for Phase III COVID-19 Clinical Trial (yahoo.com)
2 Therapeutic Solutions International Identifies and Files Patent on Novel Mechanism of Action of Its FDA Phase III Cleared JadiCell™ Treatment of COVID-19 and Delta Variant (prnewswire.com)
3 Therapeutic Solutions International Identifies Novel Biological Pathway Utilized by its Phase III Adult Stem Cell Product JadiCell™ to Stimulate Healing of Injured
4 Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung Damage Using its JadiCell™ Universal Donor Stem Cell Drug |
5 Review of TSOI’s COPD Therapy Moves Forward With IND Designation (copdnewstoday.com)
6 Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell (prnewswire.com)
7 Therapeutic Solutions International Develops Novel Stem Cell Based Therapy to Reduce Lung Scarring: Potential Solution to Post COVID-19 Lung Deterioration (prnewswire.com)